Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
December 25, 2017
- Mylan EPD to Take Over EpiPen from Pfizer in Japan
December 22, 2017
- Mitsubishi Tanabe Seeks to Call Off Cell Therapy Deal with South Korea’s KLS
December 21, 2017
- Pfizer, Maruishi File Precedex for Pediatric Use
December 21, 2017
- Otsuka Partners with US Biotech X-Chem on Oncology Drug Discovery
December 21, 2017
- GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
- Fujifilm Grabs Stake in Genome Editing Startup, Makes Inroads into Gene Therapy Space
December 20, 2017
- JCR, Medipal to Form US Joint Venture Next Month
December 20, 2017
- Ono Cuts Computational Drug Discovery Deal with Schrödinger
December 20, 2017
- Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
- Pfizer to Lift Selara Shipment Adjustment, Normalizing Supply of All Hurricane-Hit Products
December 20, 2017
- Mundipharma to Enter Japanese Anesthesia Market with Remimazolam Licensed from German Company
December 20, 2017
- Janssen, Taiho to Copromote Psoriasis Med Guselkumab
December 19, 2017
- Kyowa Kirin’s Burosumab Gains European Panel Backing for Conditional Approval
December 19, 2017
- Pfizer, Takeda to End Xeljanz Distribution/Copromotion Scheme
December 19, 2017
- Takeda/TiGenix Cell Therapy for Crohn’s Disease Complication Gets European Panel Nod
December 19, 2017
- Authorized Generic Makers Thrive in April-September, but Pricing Overhaul Casts Cloud on Their Outlook
December 18, 2017
- Sawai Wins Supreme Court Victory in Elplat Patent Suit
December 18, 2017
- Pfizer’s Ibrance Now Available in Japan
December 18, 2017
- Ethical Drug Sales Up 6.4% in October on Keytruda/SGLT-2 Boost: Crecon
December 18, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…